Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2024
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 August 2021Published: 26 March 2008
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 September 2020
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 February 2025
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2025
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2025
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 November 2025
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for previously treated severe nasal polyps [ID1659]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC